Fig. 2: Identification of oncology drugs that differentially target small or large intestine-derived monolayers.
From: Differential toxicity to murine small and large intestinal epithelium induced by oncology drugs
a Number of drug hits from toxicity screen. b Selectivity of the high concentration of each drug in decreasing total cell number. Shaded region represents a selectivity <20%. Each circle is a drug, and blue circles are drugs selective (>20%) for the small intestine. Labeled compounds: MTX, methotrexate; PEM, pemetrexed; CP, cyclophosphamide; ERL, erlotinib. SI: small intestine; LI: large intestine; Tox: toxicity. c, d Small and large intestine-derived monolayers were treated with a 7–8 point dose-response of cyclophosphamide, methotrexate, and erlotinib, and change in cell number (c) or number of proliferative cells (d) relative to untreated cells are depicted. n = 3 wells. Fitted curves were used to calculate the LC50, concentration required to kill 50% of cells, listed in Supplementary Table 3.
